

VENATOR

**Second Quarter 2020 Results
Presentation**
August 4, 2020

This presentation includes “forward-looking statements” within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events, future revenue or performance, capital expenditures, financing needs, plans or intentions relating to acquisitions, business trends and other information that is not historical information. When used in this presentation, the words “estimates,” “expects,” “anticipates,” “projects,” “plans,” “intends,” “believes,” “forecasts,” or future or conditional verbs, such as “will,” “should,” “could,” or “may,” and variations of such words or similar expressions are intended to identify forward-looking statements. All forward-looking statements, including, without limitation, management’s examination of historical operating trends and data, are based upon our current expectations of future events and various assumptions which may not be realized or accurate. Our expectations, beliefs and projections are expressed in good faith, and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved. We undertake no obligation to update or revise forward-looking statements which may be made to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events.

There are a number of risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements contained in this presentation. Such risks, uncertainties and other important factors include, among others: the impacts and duration of the global outbreak of the Coronavirus Disease 2019 pandemic on the global economy and all aspects of our business, including our employees, customers, suppliers, partners, results of operations, financial condition and liquidity, global economic conditions, our ability to maintain sufficient working capital, our ability to access capital markets on favorable terms, our ability to transfer technology and manufacturing capacity from our Pori, Finland manufacturing facility to other sites in our manufacturing network, the costs associated with such transfer and the closure of our Pori facility, our ability to realize financial and operational benefits from our business improvement plans and initiatives, impacts on TiO₂ markets and the broader global economy from the imposition of tariffs by the U.S. and other countries, changes in raw material and energy prices, or interruptions in raw materials and energy, industry production capacity and operating rates, the supply demand balance for our products and that of competing products, pricing pressures, technological developments, legal claims by or against us, changes in government regulations, including increased manufacturing, labeling and waste disposal regulations and the classification of TiO₂ as a carcinogen in the EU, geopolitical events, cyberattacks and public health crises and other risk factors as discussed in our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC, and in our Quarterly Reports on Form 10-Q for the three months ended March 31, 2020 and June 30, 2020, filed with the SEC.

This presentation contains financial measures that are not in accordance with generally accepted accounting principles in the U.S. (“GAAP”), including EBITDA, adjusted EBITDA, adjusted EBITDA margin, free cash flow and net debt and certain ratios and other metrics derived therefrom. We have provided reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures in the Appendix to this presentation.

Second Quarter 2020 Highlights

Financial summary



<i>\$ in millions, except per share amounts</i>	2Q20	2Q19	1Q20
Revenues	456	578	532
Net (loss) income attributable to Venator	(19)	21	7
Adjusted net (loss) income attributable to Venator ⁽¹⁾	(3)	14	12
Adjusted EBITDA ⁽¹⁾	37	61	57
Diluted (loss) earnings per share	(0.18)	0.20	0.07
Adjusted diluted (loss) earnings per share ⁽¹⁾	(0.03)	0.13	0.11
Net cash provided by (used in) operating activities	38	(21)	(58)
Free cash flow ⁽³⁾	18	(50)	(85)

Venator's Path Through COVID-19

VENATOR

Robust response to mitigate challenges and navigate the COVID-19 pandemic

1Q20 onset of COVID-19

- ▶ Enhanced focus on the health and safety of our employees
- ▶ Implemented a range of measures to protect our manufacturing assets and supply chain
- ▶ Reduced cash uses and discretionary spending

During the Pandemic

- ▶ Customer-tailored approach aligning production and inventories to customer commitments
- ▶ Bolstered cost reduction initiatives and disciplined cash management
- ▶ Enhanced liquidity⁽¹⁾ position

The Path Forward

- ▶ Phased reopening of economies underway
- ▶ Pace of recovery will differ by geography and end-use application
- ▶ Disciplined management of operating rates and inventories

Actions we are taking are designed to better position Venator for the recovery


(1) Defined as cash and availability under the ABL

EBITDA Improvement Through Lower Costs **VENATOR**

>\$20 million of COVID-19 cost reduction initiatives; Existing programs on-track

Delivering EBITDA Improvement Primarily Through Lower Costs

\$ in millions



Highlights of Cost Initiatives

- ▶ Expect to deliver \$40 million⁽¹⁾ of annual adjusted EBITDA benefit from our 2019 Business Improvement Program
 - Delivered \$8 million of adjusted EBITDA benefit in 1H20
 - Expect to exit 2020 at the targeted run-rate
- ▶ Target >\$10 million⁽²⁾ of annual adjusted EBITDA benefit in our color pigments business
- ▶ Our COVID-19 actions are expected to reduce costs by >\$20 million⁽²⁾ in 2020

(1) Compared to year-end 2018 baseline

(2) Compared to year-end 2019 baseline


Titanium Dioxide

VENATOR

Stable sequential average TiO₂ price; Volumes impacted by COVID-19


Revenues

\$ in millions



Adjusted EBITDA

\$ in millions



▲ Titanium Dioxide Adjusted EBITDA margin

Second Quarter Highlights

- ▶ TiO₂ prices were stable Q/Q⁽¹⁾ and Y/Y⁽¹⁾
- ▶ Volumes declined 21% Y/Y and 16% Q/Q, primarily due to COVID-19 and broadly across geographies and products
- ▶ Volume trends improved throughout the quarter
- ▶ >\$3mm adjusted EBITDA benefit from the 2019 Business Improvement Program

Outlook

Near Term Expectations

- ▶ TiO₂ prices to remain stable globally
- ▶ Weak textile demand impacting specialty TiO₂ volumes
- ▶ Disciplined management of operating rates & inventory
- ▶ Delivery of our cost reduction initiatives

Longer Term Expectations

- ▶ Further cost reduction initiatives
- ▶ Demand to normalize after the COVID-19 pandemic
- ▶ Favorable industry fundamentals for TiO₂

(1) In local currency


Performance Additives

Volumes impacted by COVID-19

VENATOR


Revenues

\$ in millions



Adjusted EBITDA

\$ in millions



▲ Performance Additives Adjusted EBITDA margin

Second Quarter Highlights

- ▶ Average prices increased 3%⁽¹⁾ Y/Y due to product mix
- ▶ Volumes declined 16% Y/Y and 11% Q/Q, primarily due to COVID-19
- ▶ Volumes most impacted in construction and automotive applications; stable in timber treatment
- ▶ <\$1mm adjusted EBITDA benefit from the 2019 Business Improvement Program

Outlook

Near Term Expectations

- ▶ Adjusted EBITDA benefit from cost reduction initiatives
- ▶ Disciplined management of operating rates & inventory
- ▶ Gradual and uneven recovery in demand

Longer Term Expectations

- ▶ Further cost reduction initiatives
- ▶ Improve cost competitiveness to support longer-term earnings power
- ▶ Potential sale of color pigments business

(1) In local currency


Adjusted EBITDA Bridges

Second Quarter 2020




Year / Year Adjusted EBITDA Bridge

\$ in millions



Quarter / Quarter Adjusted EBITDA Bridge

\$ in millions



See Appendix for reconciliations and important explanatory notes

Free Cash Flow Considerations

\$453mm of total liquidity⁽¹⁾ as of June 30, 2020

VENATOR

\$ in millions	Actual		Estimate	Comments
	2Q20	YTD	2020E	
Adjusted EBITDA	\$37	\$94		<ul style="list-style-type: none"> ▶ Generated positive free cash flow in 2Q20 due to working capital management ▶ Assessing opportunities to further reduce cash uses ▶ Total liquidity⁽¹⁾ of \$453mm as of June 30, 2020 <ul style="list-style-type: none"> – \$188mm of cash; \$265mm available under the ABL – Successfully completed a \$225 million offering of senior secured notes due 2025 ▶ No significant debt maturities until 2024⁽⁴⁾
Capital expenditures ⁽²⁾	(16)	(46)	~(60)	
Cash interest	(4)	(18)	(40)-(45)	
Primary working capital change	15	(58)	10-30	
Restructuring	(1)	(5)	(15)-(20)	
Other	(8)	(28)	~(75)	
Cash income taxes	--	--	<(5)	
Pori cash expenses, net ⁽³⁾	(5)	(6)	~(15)	
Total free cash flow	\$18	\$(67)		

See Appendix for reconciliations and important explanatory notes

(1) Defined as cash and availability under the ABL

(2) Includes capital expenditures related to the transfer of specialty and differentiated products and excludes ~\$1 million of capital expenditures at the Pori site in 1H20

(3) Includes ~\$1 million of capital expenditures at Pori unrelated to the transfer program in 1H20

(4) Scheduled maturities of our Term Loan, Snr Unsecured and Snr. Secured bonds in 2024, 2025 and 2025, respectively. Excludes debt to affiliates, ABL refinancing in 2022 and existing short-term borrowings or repayments under the ABL

Maximize Shareholder Value

Customer-tailored approach

Focus on specialty & differentiated products

Enhance competitive position

Improve free cash flow generation

Portfolio optimization

▶ Aligning production to meet customer commitments

▶ Growth in higher value products supported by innovation

▶ Driving operational efficiencies and cost improvements

▶ Reduce cash uses and improve working capital management

▶ Potential sale of color pigments business

Pro Forma Adj. EBITDA Reconciliation



\$ in millions	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2Q19	2Q20	2Q20LTM
Net (Loss) / Income					\$ (162)	\$ (352)	\$ (77)	\$ 144	\$ (157)	\$ (170)	\$ 22	\$ (17)	\$ (199)
Net income attributable to noncontrolling interests					(2)	(7)	(10)	(10)	(6)	(5)	(1)	(2)	(6)
Net income of discontinued operations					–	(10)	(8)	(8)	–	–	–	–	–
Interest					2	30	44	40	40	41	10	12	42
Income tax expense / (benefit)					(17)	(34)	(23)	50	(8)	150	(9)	2	158
Depreciation and Amortization					93	100	114	127	132	110	29	28	111
EBITDA					\$ (86)	\$ (273)	\$ 40	\$ 343	\$ 1	\$ 126	\$ 51	\$ 23	\$ 106
Business acquisition and integration expenses					45	44	11	5	20	(1)	(1)	3	2
Separation expense, net					–	–	–	7	2	(3)	–	–	(3)
U.S. income tax reform					–	–	–	(34)	–	–	–	–	–
Purchase accounting adjustments					13	–	–	–	–	–	–	–	–
Loss / (gain) on disposition of businesses/assets					(1)	1	(22)	–	2	1	–	–	3
Certain legal settlements and related expense					3	3	2	1	–	4	1	–	3
Amortization of pension and postretirement actuarial losses					11	9	10	17	15	14	4	4	13
Net plant incident costs (credits)					–	4	1	4	(232)	20	6	2	10
Restructuring, impairment, and plant closing costs					62	220	35	52	628	33	–	5	33
Adjusted EBITDA					\$ 47	\$ 8	\$ 77	\$ 395	\$ 436	\$ 194	\$ 61	\$ 37	\$ 167
Corporate and other					29	53	53	64	43	50	10	11	47
Operating Segment Adjusted EBITDA					\$ 76	\$ 61	\$ 130	\$ 459	\$ 479	\$ 244	\$ 71	\$ 48	\$ 214

Reconciliation of U.S. GAAP to Non-GAAP Measures

VENATOR

	EBITDA		Net Income (Loss)		Diluted Earnings (Loss) Per Share ⁽¹⁾	
	Three months ended		Three months ended		Three months ended	
	June 30,		June 30,		June 30,	
	2020	2019	2020	2019	2020	2019
<i>(In millions, except per share amounts)</i>						
Net (loss) income	\$ (17)	\$ 22	\$ (17)	\$ 22	\$(0.16)	\$ 0.21
Net income attributable to noncontrolling interests	(2)	(1)	(2)	(1)	(0.02)	(0.01)
Net (loss) income attributable to Venator	(19)	21	(19)	21	(0.18)	0.20
Interest expense, net	12	10				
Income tax expense (benefit)	2	(9)				
Depreciation and amortization	28	29				
Business acquisition and integration adjustments	—	(1)	—	(1)	—	(0.01)
Certain legal expenses/settlements	3	1	3	1	0.03	0.01
Amortization of pension and postretirement actuarial losses	4	4	4	4	0.04	0.03
Net plant incident costs	2	6	2	6	0.02	0.06
Restructuring, impairment, plant closing and transition costs	5	—	5	—	0.05	—
Income tax adjustments ⁽²⁾	—	—	2	(17)	0.01	(0.16)
Adjusted⁽¹⁾	\$ 37	\$ 61	\$ (3)	\$ 14	\$(0.03)	\$ 0.13
Adjusted income tax expense ⁽²⁾			\$ —	\$ 8		
Net income attributable to noncontrolling interests, net of tax			2	1		
Adjusted pre-tax (loss) income			\$ (1)	\$ 23		
Adjusted effective tax rate			35%	35%		

See Appendix for reconciliations and important explanatory notes

Reconciliation of U.S. GAAP to Non-GAAP Measures

VENATOR

	EBITDA	Net Income (Loss)	Diluted Earnings (Loss) Per Share ⁽¹⁾
	Three months ended March 31, 2020	Three months ended March 31, 2020	Three months ended March 31, 2020
<i>(In millions, except per share amounts)</i>			
Net income	\$ 8	\$ 8	\$ 0.08
Net income attributable to noncontrolling interests	(1)	(1)	(0.01)
Net income attributable to Venator	7	7	0.07
Interest expense, net	10		
Income tax benefit	(2)		
Depreciation and amortization	28		
Business acquisition and integration expenses	1	1	0.01
Loss on disposal of businesses/assets	2	2	0.02
Amortization of pension and postretirement actuarial losses	3	3	0.03
Net plant incident costs	1	1	0.01
Restructuring, impairment, plant closing and transition costs	7	7	0.06
Income tax adjustments ⁽²⁾	—	(9)	(0.09)
Adjusted⁽¹⁾	\$ 57	\$ 12	\$ 0.11
Adjusted income tax expense ⁽²⁾		\$ 7	
Net income attributable to noncontrolling interests, net of tax		1	
Adjusted pre-tax income		\$ 20	
Adjusted effective tax rate		35 %	

See Appendix for reconciliations and important explanatory notes

Reconciliation of U.S. GAAP to Non-GAAP Measures

VENATOR

	EBITDA		Net Income (Loss)		Diluted Earnings (Loss) Per Share ⁽¹⁾	
	Six months ended June 30,		Six months ended June 30,		Six months ended June 30,	
	2020	2019	2020	2019	2020	2019
<i>(In millions, except per share amounts)</i>						
Net (loss) income	\$ (9)	\$ 20	\$ (9)	\$ 20	\$(0.08)	\$ 0.19
Net income attributable to noncontrolling interests	(3)	(2)	(3)	(2)	(0.03)	(0.02)
Net (loss) income attributable to Venator	(12)	18	(12)	18	(0.11)	0.17
Interest expense, net	22	21				
Income tax benefit	—	(8)				
Depreciation and amortization	56	55				
Business acquisition and integration expenses	1	1	1	1	0.01	0.01
Loss on disposal of businesses/assets	2	—	2	—	0.02	—
Certain legal expenses/settlements	3	1	3	1	0.03	0.01
Amortization of pension and postretirement actuarial losses	7	8	7	8	0.06	0.07
Net plant incident costs	3	13	3	13	0.03	0.12
Restructuring, impairment, plant closing and transition costs	12	12	12	12	0.11	0.11
Income tax impact of adjustments ⁽²⁾	—	—	(7)	(25)	(0.07)	(0.23)
Adjusted⁽¹⁾	\$ 94	\$ 121	\$ 9	\$ 28	\$ 0.08	\$ 0.26
Adjusted income tax expense ⁽²⁾			\$ 7	\$ 17		
Net income attributable to noncontrolling interest, net of tax			3	2		
Adjusted pre-tax income			\$ 19	\$ 47		
Adjusted effective tax rate			35 %	35 %		

See Appendix for reconciliations and important explanatory notes

(1) Our management uses adjusted EBITDA to assess financial performance. Adjusted EBITDA is defined as net income/loss before interest income/expense, net, income tax expense/benefit, depreciation and amortization, and net income attributable to noncontrolling interests, as well as eliminating the following adjustments: (a) business acquisition and integration expenses/adjustments; (b) loss/gain on disposition of business/assets; (c) certain legal expenses/settlements; (d) amortization of pension and postretirement actuarial losses/gains; (e) net plant incident costs/credits; and (f) restructuring, impairment, and plant closing and transition costs/credits. We believe that net income is the performance measure calculated and presented in accordance with U.S. GAAP that is most directly comparable to adjusted EBITDA.

Adjusted net income is computed by eliminating the after-tax amounts related to the following from net income attributable to Venator Materials PLC ordinary shareholders: (a) business acquisition and integration expenses/ adjustments; (b) loss/gain on disposition of business/assets; (c) certain legal expenses/settlements; (d) amortization of pension and postretirement actuarial losses/gains; (e) net plant incident costs/credits; and (f) restructuring, impairment, and plant closing and transition costs/credits. Basic adjusted net earnings per share excludes dilution and is computed by dividing adjusted net income by the weighted average number of shares outstanding during the period. Adjusted diluted net earnings per share reflects all potential dilutive ordinary shares outstanding during the period increased by the number of additional shares that would have been outstanding as dilutive securities.

(2) Prior to the second quarter of 2019, the income tax impacts, if any, of each adjusting item represented a ratable allocation of the total difference between the unadjusted tax expense and the total adjusted tax expense, computed without consideration of any adjusting items using a with and without approach.

Beginning in the three- and six-month periods ended June 30, 2019, income tax expense is adjusted by the amount of additional tax expense or benefit that we would accrue if we used non-GAAP results instead of GAAP results in the calculation of our tax liability, taking into consideration our tax structure. We use a normalized effective tax rate of 35%, which reflects the weighted average tax rate applicable under the various jurisdictions in which we operate. This non-GAAP tax rate eliminates the effects of non-recurring and period specific items which are often attributable to restructuring and acquisition decisions and can vary in size and frequency. This rate is subject to change over time for various reasons, including changes in the geographic business mix, valuation allowances, and changes in statutory tax rates.

We eliminate the effect of significant changes to income tax valuation allowances from our presentation of adjusted net income to allow investors to better compare our ongoing financial performance from period to period. We do not adjust for insignificant changes in tax valuation allowances because we do not believe it provides more meaningful information than is provided under GAAP. We believe that our revised approach enables a clearer understanding of the long term impact of our tax structure on post tax earnings.

(3) Management internally uses a free cash flow measure: (a) to evaluate the Company's liquidity, (b) to evaluate strategic investments and (c) to evaluate the Company's ability to incur and service debt. Free cash flow is not a defined term under U.S. GAAP, and it should not be inferred that the entire free cash flow amount is available for discretionary expenditures. The Company defines free cash flow as cash flows provided by (used in) operating activities from continuing operations and used in investing activities. Free cash flow is typically derived directly from the Company's condensed consolidated statement of cash flows; however, it may be adjusted for items that affect comparability between periods. Free cash flow is presented as supplemental information.